MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

Slides:



Advertisements
Similar presentations
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
חזק בהגנה לבבית Valsartan in Heart Failure
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
ESPRIT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Assessing A-HeFT and PEACE Eric J Topol MD Provost and Chief Academic Officer Chair, Department of Cardiovascular Medicine Cleveland Clinic Foundation.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Clinical trials in crisis Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
OPTIME CHF and PRAISE II: Recent heart failure trials Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director.
Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
BRAVO and oral GP IIb/IIIa Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Calcium channel blockers: the debate continues Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the.
PPP and Complement Inhibition Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
4S: Scandinavian Simvastatin Survival Study
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Secretory Phospholipase A 2 Inhibition with Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: Results of the VISTA-16.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Thumbs up/Thumbs down – Oct 2002 OPTIMAAL OPTIMAAL: Does the dose make the medicine? Eric J Topol MD Provost and Chief Academic Officer Chairman, Department.
OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Total Occlusion Study of Canada (TOSCA-2) Trial
Clinical Trial Commentary
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Clinical need for determination of vulnerable plaques
ACC 2004: SCD-HeFT, PROVE-IT, and SYNERGY under debate
AIM HIGH Niacin plus Statin to prevent vascular events
Beyond Current Strategies: Focus on Angiotensin Receptors
Valsartan in Acute Myocardial Infarction Trial Investigators
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Section III: Neurohormonal strategies in heart failure
American College of Cardiology Presented by Dr. Stephan Windecker
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Clinical Trial Commentary
LRC-CPPT and MRFIT Content Points:
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
ARISE Trial Aggressive Reduction of Inflammation Stops Events
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Clinical Trial Commentary
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and Vascular Biology at the Cleveland Clinic Dr Robert Califf Professor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University

Statin therapy post-MI Previous statin trials have excluded patients who were within the first several months after acute coronary syndromes. No outcome data are available for the use of statins in this several month “window”. One theoretical risk of early statin therapy is that of plaque destabilization during the remodelling process. MIRACL

Design 3000 patients following an acute coronary event were randomized to either 80 mg atorvastatin or placebo for a period of 3 months. The primary endpoint was a composite of death, MI, and refractory recurrent ischemia requiring hospitalization. The study was originally powered to detect a 25% difference between atorvastatin and placebo in the primary endpoint. MIRACL

Results 14.8% of patients on atorvastatin demonstrated a primary endpoint vs 17.4% on placebo (16% reduction, p=0.048). This 16% reduction was primarily due to a favorable effect of atorvastatin on recurrent symptomatic myocardial ischemia (26% reduction, p=0.02). Levels of LDL fell by 40% in those patients treated with atorvastatin. MIRACL

Clinical implications This trial confirms that it’s safe to begin treating patients with higher LDL cholesterol levels as soon as possible after an acute coronary event. The indications for treating a low LDL at the time of admission remain unclear, however. Benefit from statin therapy may also be directly related to the presence of a high C- reactive protein (CRP) level and the presence of oxidized LDL. MIRACL

Additional points To date, there has not been a trial of atorvastatin showing a reduction in mortality. A trial comparing pravastatin and atorvastatin after acute coronary syndromes is now underway. The “class effect” of statins, ACE inhibitors, and other agents is becoming an increasingly important question in clinical trials. MIRACL

Patient population This study included 5010 patients from 300 centers in the US and Europe. Most patients were in NYHA class II (61.7%) or III (36.2%) at baseline. The ratio of men to women was about 4:1. 90% of patients enrolled were white. 93% of patients were on ACE inhibitors and 35% were on beta-blockers at the time of enrollment. Val-HeFT

Design Patients were randomized to either placebo or valsartan (beginning at 40 mg BID and titrating up to 160 mg BID). Primary endpoints included all-cause mortality (time to death) and combined all- cause mortality and morbidity. The latter endpoint comprised all-cause mortality, hospitalization for heart failure, resuscitated sudden death, and the need for therapeutic doses of an IV inotropic or vasodilating agent for at least 4 hours. Val-HeFT

Primary endpoints Val-HeFT Primary endpoints Valsartan N=2511 Placebo N=2499 Relative risk (95% CI) p-value All-cause mortality 495 (19.7%) 484 (19.4%) 1.02 ( ) 0.8 Combined all-cause mortality and morbidity 723 (28.8%) 801 (32.1%) 0.87 ( ) CI confidence interval

Results Quality of life was better in those patients taking valsartan compared to placebo. Most of the reduction in morbidity occurred in hospitalizations for heart failure, and in patients who weren’t taking ACE inhibitors at enrollment (45% reduction). A trend toward a negative effect was seen in patients on valsartan who were also taking both beta-blockers and ACE inhibitors. Val-HeFT

Clinical implications This study confirms that ACE intolerant patients with heart failure should be on an angiotensin receptor blocker (ARB). Caution is warranted when adding an ARB to patients who are already taking both an ACE inhibitor and beta-blockers. This cannot be advocated as the standard of practice. Beta-blockers are not being used to treat heart failure in clinical practice to the extent that they should be. Val-HeFT

Additional trial comparisons In ELITE-2, which looked at a different ARB, those patients on beta-blockers appeared to do worse on the ARB compared to those who were not on the beta-blockers. This situation is not analogous to Val-HeFT, because the group that did poorly in Val- HeFT was on the combination ARB, ACE inhibitor and beta-blocker. The VALIANT (N14 500) and CHARM (N7000) trials should clarify this issue. Val-HeFT

The individual perspective Vice-Presidential candidate Dick Cheney is status post acute-MI and has an ejection fraction of 40%. Original reports prior to his most recent MI suggested that Mr Cheney had been taking only aspirin and a statin agent. He should now be on both a beta-blocker and an ACE inhibitor. One physician has even suggested that Mr Cheney should be carrying an automatic external defibrillator.